House Committee on Insurance: HB 2536

Texas Insight was asked to cover the following Bill discussed in the House Committee on Insurance: HB2536, by Oliverson, relating to transparency related to drug costs. ~ LBB Fiscal Note Summary. No significant fiscal implication to the State is anticipated. Bill Summary. The bill would require pharmaceutical drug manufacturers (PDMs) to annually report to the Health and Human Services Commission (HHSC) on the current wholesale acquisition costs of FDA-approved drugs sold in the state. HHSC would be required to develop a website to provide this information to the public. The bill would also require PDMs to report, and HHSC to publish, information on certain drug price increases. The bill would also require Pharmacy Benefit Managers and Health Benefit Plan Issuers to submit reports to HHSC, and require HHSC to publish those reports online. ~ Representative Oliverson explained the Committee Substitute. The Vice Chair stated that the substitute deals with transparency in pharmac